Neurosurgery published the two-year results of Redwood City, Calif.-based Nevro's SENZA-RCT study, according to Street Insider.
This study marks the largest prospective randomized clinical trial on spinal cord stimulation to date, and is the first study to compare the efficacy of SCS therapies.
Here are six observations:
1. The study found Nevro's Senza HF10 therapy more effective than traditional low-frequency SCS therapy.
2. HF10 therapy resulted in a 76.5 percent back pain responder rate compared to 49.3 percent rate for traditional SCS therapy.
3. HF10 therapy also saw a 72.9 percent leg pain responder rate compared to 49.3 percent rate for traditional SCS therapy.
4. Compared to traditional SCS therapy, HF10 therapy demonstrated improved and durable pain relief.
5. Patients receiving HF10 therapy did not experience paresthesia.
6. The FDA approved Nevro's Senza SCS system in May 2015.